Aisling Capital

Founded 2000

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 96
Average round size
info
The average size of a deal this fund participated in
$49M
Portfolio companies 69
Rounds per year 4.57
Lead investments 15
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.35
Exits 46
Key employees 7
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical Device
Summary

Aisling Capital is the famous VC, which was founded in 2000. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the New York.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Aisling Capital, startups are often financed by Vivo Capital, New Enterprise Associates, Sofinnova Investments. The meaningful sponsors for the fund in investment in the same round are Vivo Capital, New Enterprise Associates, Venrock. In the next rounds fund is usually obtained by OrbiMed, Kearny Venture Partners, Polaris Partners.

The top amount of exits for fund were in 2014. The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. The average startup value when the investment from Aisling Capital is 100-500 millions dollars. Considering the real fund results, this VC is 0 percentage points less often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Aisling Capital performs on 12 percentage points more the average number of lead investments.

The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Loxo Oncology, Zeltiq Aesthetics, BridgeBio We can highlight the next thriving fund investment areas, such as Therapeutics, Medical.

We also calculated 7 valuable employees in our database.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Aisling Capital:
Typical Co-investors
Aisling Capital is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Aisling Capital:

Funds with similar focus

Funds from United States, New York
Funds with similar focus located in United States, New York:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
1
$96M12 Apr 2021 Atlanta Georgia United States

Biotechnology
Medical
Therapeutics
1
$95M12 Mar 2021 Basel Basel-City Switzerland

Biomea Fusion

Biotechnology
Life Science
Therapeutics
1
$56M06 Jan 2021 California Redwood City United States

Reneo Pharmaceuticals

Biotechnology
Medical
Pharmaceutical
1
$95M09 Dec 2020 California San Diego United States

Elevation Oncology

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
1
$65M18 Nov 2020 New York United States

Talaris Therapeutics

Biotechnology
Health Care
Therapeutics
1
$115M06 Oct 2020 Massachusetts United States

Biotechnology
Medical
Therapeutics
1
$96M24 Sep 2020 Basel Basel-City Switzerland

Elevation Oncology

Biopharma
Biotechnology
Health Care
Life Science
Pharmaceutical
1
$32M21 Jul 2020 New York United States

Verona Pharma

Biotechnology
Pharmaceutical
Therapeutics
n/a
$200M17 Jul 2020 England London United Kingdom
News
Garuda Therapeutics Raises $72M in Series A Financing

– Garuda Therapeutics from Cambridge develops off-the-shelf, durable blood stem cell therapies.
– Series A funding of $72m brings company valuation to more than $1b.
– The round was led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant Asset Management, Ridgeback Capital Investments, Monashee Investment Management, Sectoral Asset Management, National Resilience, Inc. (Resilience), Mass General Brigham Ventures, among others.

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Aisling Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: